Form 4 Filing for Jan Pinkas

Jan Pinkas, Chief Scientific Officer of CRESCENT BIOPHARMA, INC., reported the sale of 1288 ordinary shares on June 22, 2026. The shares were sold at a weighted average price of $17.99, with individual transactions ranging from $16.88 to $18.86. These sales were executed to cover tax withholding obligations related to the settlement of restricted stock units granted on December 15, 2025. The sales were conducted under a Rule 10b5-1 trading plan adopted on February 26, 2026. Following these transactions, Pinkas holds 22,239 shares. The filing also includes an undertaking to provide detailed information on individual sale prices upon request. The reporting owner signature was provided by Barbara Bispham, as attorney-in-fact for Jan Pinkas.